Evidence — LL-37
peptide · asset evidence level: emerging
Evidence quality breakdown (linked documents)
expert_opinion: 2mechanistic: 1
Linked source documents (3)
- Integrative Peptide Therapy — Clinical Reference Protocol (Demo Import) (physician_protocol · expert_opinion)
- Synergistic Effects of Thymosin Alpha-1, BPC-157, TB-500, LL-37, MOTS-c, SS-31, CJC-1295 with DAC, Ipamorelin, and Nicotine on Lyme Disease Reversal in a Borrelia burgdorferi-Infected Murine Model.docx (physician_protocol · expert_opinion)
- LL-37 (Cathelicidin): Mechanistic Overview (internal_protocol · mechanistic)
Provider dosing references (Stage 9, source-attributed)
100 mcg SC daily or every other day — Practitioner Peptide Dosing Reference (commonly published ranges)
Dosing claims (5) · Safety claims (2)
Extracted claims are provider-review scaffolding, stored verbatim with source attribution — not recommendations or dosing guidance.